Compare Home Depot Inc (HD) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Home Depot Inc vs Recursion Pharmaceuticals Inc — how do they compare? Home Depot Inc trades at $296.38 (market cap $294.79B), while Recursion Pharmaceuticals Inc trades at $4.01 (market cap $2.14B). The key difference: Home Depot Inc is far larger — about 137.8× Recursion Pharmaceuticals Inc's market cap, and Home Depot Inc pays a 3.15% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Home Depot Inc for 139 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| HD | RXRX | |
|---|---|---|
Market Cap | $294.79B | $2.14B |
Volume | 8,693,917 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $391.90 | $6.79 |
52-Week Low | $281.15 | $2.84 |
Typical Hold Time | 139 Days | 22 Days |
Enterprise Value | $355.27B | $1.66B |
Dividend Yield | 3.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Home Depot (HD) trades at $285.77, down 0.32% with bearish technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (ROE 104.3%, net margin 8.41%). Revenue grew to $159.51B in 2025, though margins face pressure from housing market headwinds. Analysts maintain a bullish consensus with a $379.93 price target (58.7% buy ratings). Recent institutional activity shows mixed positioning amid weak big-ticket demand.
HD offers long-term value with analyst upside of 33% but faces near-term risks from rising mortgage rates and margin compression. The Pro business and digital initiatives provide growth levers, while technical weakness suggests cautious entry points. Investors should weigh strong cash flow generation against cyclical housing exposure.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
